Literature DB >> 8342567

Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia.

H Okumura1, S Nakamura, S Ohtake, T Yoshida, K Kobayashi, Y Okabe, S Matano, K Kyohda, T Matsuda.   

Abstract

A 47-year-old woman was diagnosed with acute myelomonocytic leukemia (AMMoL) and was treated with combination chemotherapy. After one cycle of remission induction therapy, she entered into complete remission and then received three cycles of consolidation therapy. A month after the last consolidation therapy, she was diagnosed with having the complication of chemotherapy-related HUS (C-HUS). The C-HUS improved after initiation of plasma exchange and antiplatelet therapy. In the present case, it seems that the antileukemic agents might play an important role in the development of C-HUS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8342567     DOI: 10.1002/ajh.2830440115

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  2 in total

1.  Acute leukemia: an association with atypical hemolytic uremic syndrome.

Authors:  Hyewon Hahn; Il Soo Ha; Hyoung Soo Choi; Hee Young Shin; Hae Il Cheong; Hyo Seop Ahn; Yong Choi
Journal:  Pediatr Nephrol       Date:  2003-05-16       Impact factor: 3.714

2.  Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report.

Authors:  Ludovica Facchini; Maurizio Lucchesi; Alessia Stival; Rosa Maria Roperto; Francesca Melosi; Marco Materassi; Silvia Farina; Veronica Tintori; Maurizio de Martino; Iacopo Sardi
Journal:  J Med Case Rep       Date:  2017-07-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.